Loeillot Olivier sold $977K of RGEN

Loeillot Olivier (Chief Executive Officer) sold 5,426 shares of REPLIGEN CORP (RGEN) at $180.00 ($0.98M total) on 2026-08-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Loeillot Olivier
Published Aug 21, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RGEN
Neutral
medium confidence
Mentioned
$RGEN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGENNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or personal tax planning not disclosed.

Relevance 4/10Novelty 5/10Timing: today

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$RGENNeutralMedium confidence
Context

CEO Olivier Loeillot sold 5,426 shares for $976,680 via a 10b5‑1 plan, reducing his stake to 54,246 shares.

Expected impact

Potential minor downward pressure, likely within normal volatility range.

Evidence & confidence

The sale amount is under $1M and represents a small percentage of total holdings, limiting market impact.

Market effects

Minimal effect on biotech/healthcare sector; insider sales are routine.

No regional impact beyond investor perception of RGEN.

Limited global relevance; only relevant to RGEN shareholders.

Counterpoint

The sale could be a routine liquidity event, not a bearish signal.

Key entities

  • Loeillot Olivier

    Chief Executive Officer of Repligen Corp.

  • Repligen Corp

    Biopharmaceutical company listed on NASDAQ under ticker RGEN.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.